Your shopping cart is currently empty

H111-H7 is an inhibitor of the E3 ubiquitin ligase 27 containing the WW domain (WWP2), with a KD value of 717 nM. In a unilateral ischemia-reperfusion (UIR) mouse model, H111-H7 inhibits the expression of WWP2, restores the level of succinate dehydrogenase complex subunit C (SDHC), and slows the progression from acute kidney injury (AKI) to chronic kidney disease (CKD). H111-H7 is applicable for studying the transition from AKI to CKD.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | H111-H7 is an inhibitor of the E3 ubiquitin ligase 27 containing the WW domain (WWP2), with a KD value of 717 nM. In a unilateral ischemia-reperfusion (UIR) mouse model, H111-H7 inhibits the expression of WWP2, restores the level of succinate dehydrogenase complex subunit C (SDHC), and slows the progression from acute kidney injury (AKI) to chronic kidney disease (CKD). H111-H7 is applicable for studying the transition from AKI to CKD. |
| Targets&IC50 | WWP2:717 nM (Kd) |
| Molecular Weight | 327.8 |
| Formula | C13H10ClNO3S2 |
| Cas No. | 220965-54-8 |
| Smiles | O=C(C=1SC(SCC2=CC=C(Cl)C=C2)=C(C1)N(=O)=O)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.